Drug intelligence / Profile preview

limosilactobacillus fermentum ABF21069

Development stage: Preclinical
Lead developer: AceBiome
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Limosilactobacillus fermentum ABF21069 is a research-stage probiotic bacterial strain investigated for its potential therapeutic effects on obesity and metabolic dysfunction-associated fatty liver disease (MAFLD). As a live biotherapeutic, it functions by modulating the gut microbiota and host metabolism. Preclinical evidence suggests that ABF21069 produces exopolysaccharides and downregulates intestinal sugar transport genes, thereby reducing sugar absorption. Furthermore, it has been shown to enhance lipid metabolism by increasing the expression of genes involved in β-oxidation, thermogenesis, and lipolysis, while simultaneously reducing hepatic inflammation and fat accumulation. In mouse models, it demonstrated synergistic efficacy when administered in combination with Lactobacillus gasseri BNR17, leading to significant reductions in body weight and serum leptin levels.

Other names: Limosilactobacillus fermentum ABF21069L. fermentum ABF21069

Beyond the preview

Go deeper on limosilactobacillus fermentum ABF21069.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on limosilactobacillus fermentum ABF21069.

Explore the full profile